Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | PGR | P06401 | 1/20 | 0.32 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.31 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.31 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | HTR7 | P34969 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1928882 | 0.85 | PDGFRB (0.34) | LMNAPDGFRBPTPN2PTPN1HPGD | |
| SCHEMBL9612900 | 0.79 | NPC1 (0.37) | HSD11B1MAPTSLC6A2 | |
| SCHEMBL28954321 | 0.77 | MEN1 (0.42) | LMNAMAPTHPGDTP53 | |
| SCHEMBL28841479 | 0.74 | PDGFRB (0.42) | LMNAMAPTPDGFRBPTPN2PTPN1 | |
| SCHEMBL22147810 | 0.67 | KDM4E (0.38) | LMNAMAPTPDGFRBPTPN2PTPN1 | |
| SCHEMBL24398363 | 0.64 | GAA (0.44) | LMNAPDGFRBPTPN2PTPN1HPGD | |
| SCHEMBL16711487 | 0.64 | GAA (0.44) | LMNAPDGFRBPTPN2PTPN1HPGD | |
| SCHEMBL11941264 | 0.64 | GAA (0.44) | LMNAPDGFRBPTPN2PTPN1HPGD | |
| SCHEMBL21912879 | 0.64 | PDGFRB (0.41) | LMNAPDGFRBPTPN2PTPN1HPGD | |
| SCHEMBL18073498 | 0.62 | GRIA1 (0.43) | LMNAMAPTPTPN2PTPN1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7956192-B2 | Carbene containing metal complexes as OLEDs | THE UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2011-06-07 | — | — | US | disclosed |
| US-20090302754-A1 | CARBENE CONTAINING METAL COMPLEXES AS OLEDS | TSAI JUI-YI | 2009-12-10 | — | — | US | disclosed |
| US-7598388-B2 | Can stabily emit light with various spectra, including high energy blue spectra; tris(1-(2'-(9',9'-dimethyl)fluorenyl)-3-methyl-imidazolin-2-ylidene-C,C3') iridium(III); organic light emitting devices; combining L, a carbene ligand precursor, with an organic solvent at about 175 degrees C. | THE UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2009-10-06 | — | — | US | disclosed |
| WO-2005113704-A2 | LUMINESCENT COMPOUNDS WITH CARBENE LIGANDS | THE UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2005-12-01 | — | — | WO | disclosed |
| US-20050258742-A1 | Carbene containing metal complexes as OLEDs | UNIVERSAL DISPLAY CORPORATION | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090302754-A1 | CARBENE CONTAINING METAL COMPLEXES AS OLEDS | OPRD1, OGFRL1, OCIAD1 | HSD11B1 906/4885LMNA 503/4885HIF1A 3921/4885 |
| US-20050258742-A1 | Carbene containing metal complexes as OLEDs | OPRD1, OGFRL1, OCIAD1 | HSD11B1 906/4885LMNA 503/4885HIF1A 3921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.